Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME

Key Points

• Pictet Asset Management Holding SA opened a new Q4 position in Zymeworks by purchasing 73,627 shares (≈$1.97M), and institutional investors collectively own about 92.89% of the company.
• Analyst sentiment is generally positive with a MarketBeat consensus of "Moderate Buy" and a consensus price target of $37.89, while several firms have raised ratings and targets (e.g., Leerink to $58, HC Wainwright to $46, Truist to strong-buy).
• Zymeworks has a market cap of ≈$1.98B and a 1-year trading range of $10.86–$29.75, but reported a loss last quarter (EPS -$0.55) with a negative net margin, reflecting ongoing unprofitability.

Pictet Asset Management Holding SA purchased a new position in shares of Zymeworks Inc. (NASDAQ:ZYME - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 73,627 shares of the company's stock, valued at approximately $1,966,000. Pictet Asset Management Holding SA owned approximately 0.10% of Zymeworks at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Federated Hermes Inc. boosted its stake in shares of Zymeworks by 0.3% during the 3rd quarter. Federated Hermes Inc. now owns 182,847 shares of the company's stock worth $3,123,000 after acquiring an additional 577 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Zymeworks by 25.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company's stock worth $96,000 after acquiring an additional 731 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Zymeworks by 29.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company's stock worth $62,000 after acquiring an additional 1,131 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Zymeworks by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company's stock worth $386,000 after acquiring an additional 1,427 shares in the last quarter. Finally, Optiver Holding B.V. purchased a new stake in shares of Zymeworks during the 3rd quarter worth approximately $26,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ZYME shares. Leerink Partners boosted their price target on Zymeworks from $52.00 to $58.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Zymeworks in a research note on Monday, April 20th. HC Wainwright boosted their price target on Zymeworks from $32.00 to $46.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Truist Financial raised Zymeworks to a "strong-buy" rating in a research note on Monday, April 27th. Finally, Stifel Nicolaus upped their target price on Zymeworks from $40.00 to $47.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.89.

Zymeworks Stock Performance

ZYME stock opened at $26.78 on Tuesday. Zymeworks Inc. has a 1 year low of $10.86 and a 1 year high of $29.75. The stock's 50 day moving average price is $25.39 and its 200 day moving average price is $23.88. The firm has a market cap of $1.98 billion, a P/E ratio of -24.80 and a beta of 1.20.

Zymeworks (NASDAQ:ZYME - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.55) earnings per share (EPS) for the quarter. Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. The company had revenue of $2.52 million during the quarter. On average, research analysts predict that Zymeworks Inc. will post 0.97 earnings per share for the current year.

Zymeworks Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks' innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.